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S U M M A R Y
Background: Crimean-Congo hemorrhagic fever (CCHF) is one of the viral hemorrhagic fevers caused by
tick bites. Common symptoms of the infection are fatigue, high fever, headache, and myalgia. In some
patients hemorrhage may accompany these symptoms and is a sign of a poor prognosis. Typical
laboratory changes are thrombocytopenia, leukopenia, elevation of aspartate aminotransferase (AST),
alanine aminotransferase (ALT), creatine phosphokinase (CPK), and lactate dehydrogenase (LDH), and
prolongation of prothrombin time (PT) and activated partial thromboplastin time (aPTT). Mortality rates
vary between 3% and 30%. The aim of this study was to determine the factors affecting the prognosis of
CCHF.
Methods: A total of 70 patients with a diagnosis of CCHF who were followed at our clinic between 2005
and 2008 were included in this study. As well as patient clinical history, biochemical parameters tested
during the ﬁrst 5 days and the prognosis were evaluated. Findings were compared between patients who
died and those who recovered. Non-parametric statistical tests were used for the statistical analysis.
Results: When the laboratory parameters of patients who died and recovered were compared, PT, aPTT,
international normalized ratio (INR), AST, LDH, ﬁbrinogen, C-reactive protein (CRP), high-sensitivity CRP
(hs-CRP), D-dimer, IgM, IgG,
C3 and C4 levels, and platelet count were found to be positively related with fatality. On the other
hand, there was no signiﬁcant difference between groups regarding ALT, CPK, prealbumin,
ceruloplasmin, protein C, protein S, and antithrombin III levels, and white blood cell counts.
Conclusions: It is essential to determine the possibility of a fatal prognosis in CCHF patients using clinical
history and biochemical parameters so that the necessary precautions can be taken.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Crimean-Congo hemorrhagic fever (CCHF) is caused by the
CCHF virus, which is a member of the Nairovirus genus of the
Bunyaviridae family. The main vectors responsible for the spread of
this infection are Hyalomma ticks. The disease has been reported in
more than 30 countries and the fatality rate varies between 3% and
30%.1 People living in endemic areas and working in farming have
the highest risk for the disease.2 Health employees working in
institutes that follow CCHF patients are the second most important
risk group.3 The pathogenesis of the disease has not yet been
completely explained. The main pathological mechanism is
believed to be vascular endothelial damage and the main target
is thought to be the reticuloendothelial system.4 The most* Corresponding author. Tel.: +90 312 5962794; fax: +90 312 3186690.
E-mail address: dbarisozturk@yahoo.com (B. Ozturk).
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doi:10.1016/j.ijid.2011.06.005commonly observed symptoms are fatigue, high fever, headache,
myalgia, nausea, and vomiting.5
Although most CCHF cases are mild, in some cases the prognosis
is extremely severe.1 Several studies have been performed to
anticipate the severity of the disease. The ﬁrst study was performed
by Swanepoel et al. in 1989.6 In recent years, many studies have been
conducted in Turkey to evaluate the prognosis of the disease.7–10
We aimed to estimate the prognosis of the disease by using
parameters that have been evaluated for the ﬁrst time in this study,
along with clinical and biochemical parameters that have been
investigated before.
2. Methods
A total of 70 patients with a diagnosis of CCHF, who were
followed at the Infectious Diseases and Clinical Microbiology Clinic
of Dıs¸ kapı Yıldırım Beyazıt Research and Training Hospital
between the summer of 2005 and the summer of 2008, were
included in this study.ses. Published by Elsevier Ltd. All rights reserved.
B. Ozturk et al. / International Journal of Infectious Diseases 16 (2012) e89–e93e902.1. Patient selection
Patients who presented to our clinic with general disease
symptoms such as high fever, fatigue, and headache and who had
bicytopenia and elevated liver function tests were assigned a pre-
diagnosis of CCHF. The diagnosis was conﬁrmed in all of the
patients (n = 70) by speciﬁc IgM and/or real-time PCR assay at the
reference laboratory in Turkey.
2.2. Research method
A speciﬁcally designed follow-up form was used for each patient.
The patient’s clinical history was noted on the ﬁrst part of the form.
The second part was designed to evaluate the presence of common
symptoms of CCHF, such as high fever, headache, fatigue, nausea,
vomiting, myalgia, and diarrhea. Moreover, parameters such as
aspartate aminotransferase (AST), alanine aminotransferase (ALT),
creatine phosphokinase (CPK), lactate dehydrogenase (LDH), white
blood cell count (WBC), platelet count, prothrombin time (PT),
international normalized ratio (INR), activated partial thromboplas-
tin time (aPTT), ﬁbrinogen, C-reactive protein (CRP), D-dimer,
prealbumin, high-sensitivity CRP (hs-CRP), ceruloplasmin, protein C,
protein S, antithrombin III, immunoglobulin M (IgM), IgA, IgG,
complement 3 (C3), and C4, which were studied in the ﬁrst 5 days of
the disease, were recorded. The last part of the form was used to
record information for patients who had hemorrhages during their
follow-up, including the ﬁrst day of hemorrhage, the origin of the
hemorrhage (epistaxis, gingiva, vaginal, skin, hematemesis, or
melena), the duration of bleeding, and hemoglobin levels. Hemor-
rhages were divided into two groups: minor (with one only of
epistaxis, gingival, vaginal, or skin hemorrhages) and major (with
hematemesis or melena) bleeding groups.
The date of death of patients who died and the date of discharge
for patients who recovered were also recorded.
2.3. Criteria for discharge
Patients whose complaints had diminished and who had a
platelet count >150  109/l were discharged.Table 1
Comparison of fatal and non-fatal CCHF cases in terms of epidemiological history and 
Non-f
Sex, n (%)
Female 25 (7
Male 36 (9
Age (years), mean  SD 50.5 
Tick exposure, n (%) 47 (8
Days from disease onset to hospital admission, mean  SD 3.75 
Symptoms, n (%)
Fever 53 (8
Headache 37 (8
Fatigue 58 (8
Nausea/vomiting 43 (8
Myalgia 42 (8
Diarrhea 9 (69
Days from start of symptoms to onset of bleeding, mean  SD 4.2  
Duration of bleeding (days), mean  SD 2.7  
Bleeding symptoms, n (%) 18 (6
Bleeding sites, n (%)
Melena 0 
Hematemesis 1 (11
Vaginal bleeding 5 (50
Epistaxis 9 (60
Gingival bleeding 2 (20
Skin bleeding 2 (20
Bleeding sites, n (%)
Minor 17 (1
Major 1 (10
CCHF, Crimean-Congo hemorrhagic fever; SD, standard deviation.2.4. Statistical analysis
Patients were grouped into two according to their survival
status: died or discharged with recovery. SPSS 15.0 program (SPSS
Inc., Chicago, IL, USA) was used for the statistical analysis. Groups
were compared with the Mann–Whitney U-test, Wilcoxon test,
and Chi-square test by using parameters of demographic
characteristics, clinical history (e.g., time to hospital presentation,
tick contact, etc.), symptoms, presence of hemorrhage, the
duration and location of bleeding, and hematological–biochemical
parameters. A p-value of <0.05 was accepted as signiﬁcant.
Receiver operating characteristic curve (ROC) analysis was
performed for values that were statistically signiﬁcant, and
sensitivity and speciﬁcity values were calculated.
3. Results
Thirty-eight patients out of 70 were male (54.3%) and 32 were
female (45.7%). The mean age of the patients was 49.6  18.4 years.
Most of the patients resided in rural areas and were involved in
farming or stockbreeding businesses. Only four of the patients lived in
a large city, but they all had a history of visiting rural areas. While 53
(75.7%) patients had a history of tick bite and/or tick contact, 17
(24.3%) had no such history. At least one systemic bleeding was
present in 27 (38.6%) patients; 43 (61.4%) patients did not have any
hemorrhages. While 61 patients were discharged with recovery
(87.1%), nine patients (12.9%) died in the hospital. None of the
patients were treated with antiviral drugs.
The clinical history of the patients is presented in Table 1,
according to their survival status (non-fatal CCHF and fatal CCHF).
There was a statistically signiﬁcant difference between the fatal
CCHF and non-fatal CCHF groups regarding the presence of
bleeding symptoms. On the other hand, no signiﬁcant differences
were found between the groups in terms of other clinical history
variables such as age, gender, tick contact, days from disease onset
until hospital admission, days until the onset of bleeding, and
duration of bleeding. The mean hospitalization period was 11.2
days and the mean number of days before death was seven.bleeding symptoms
atal CCHF (n = 61) Fatal CCHF (n = 9) p-Value
8.1) 7 (21.9) p = 0.07
4.7) 2 (5.3)
 18.2 41.3  18.6 p = 0.163
8.7) 6 (11.3) p = 0.678
 1.6 3.22  1.1 p = 0.515
6.9) 8 (13.1) p = 0.584
4.1) 7 (15.9) p = 0.468
6.6) 9 (13.4) p = 1.000
4.3) 8 (15.7) p = 0.427
5.7) 7 (14.3) p = 0.714
.2) 4 (30.8) p = 0.055
1.3 3.4  1.9 p = 0.290
1.7 4  1.6 p = 0.070
6.7) 9 (33.3) p < 0.001
9 (100) p < 0.001
.1) 8 (88.9) p < 0.001
) 5 (50) p = 0.019
) 6 (40) p = 0.002
) 8 (80) p < 0.001
) 8 (80) p < 0.001
00) 0 -
) 9 (90)
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and fatigue, the patients also experienced headache, nausea,
vomiting, and diarrhea. There was no statistically signiﬁcant
difference between the groups regarding the frequency of these
symptoms (Table 1).
In the 27 patients with bleeding symptoms, the most common
form of bleeding was epistaxis. Melena, hematemesis, vaginal,
gingival, and skin bleeding, were the other forms of hemorrhage
experienced (Table 1). With regard to the origin of hemorrhage, the
difference between the non-fatal CCHF and fatal CCHF groups was
statistically signiﬁcant. When the minor and major bleeding
groups were evaluated, no death was experienced in the minor
bleeding group, and 90% of patients in the major bleeding group
died (Table 1).
The results of biochemical and hematological laboratory tests
performed after admission are presented in Table 2. According toTable 2
Laboratory ﬁndings in fatal and non-fatal CCHF cases (mean  SD)
Non-fatal CCHF (n = 61) 
AST (U/l) 287  387 
ALT (U/l) 137  145 
LDH (U/l) 821  402 
CPK (U/l) 588  695 
PT (s) 13.6  3 
INR 1.7  4.39 
aPTT (s) 46.8  9.8 
WBC ( 109/l) 2.849  1.703 
Platelets ( 109/l) 37.393  25.086 
Fibrinogen (mg/dl) 395  159 
CRP (mg/l) 14  17 
D-dimera (ng/ml) 4425  3479 
Prealbumin (mg/dl) 0.14  0.06 
hs-CRP (mg/l) 16.8  20.2 
Ceruloplasmin (mg/dl) 0.3  0.08 
Protein Cb (%) 87.9  30.9 
Protein Sb (%) 55.8  19.1 
Antithrombin IIIb (%) 105.4  22.9 
IgMc (mg/dl) 2.11  1.05 
IgAc (mg/dl) 2.89  1.34 
IgGc (mg/dl) 15.51  3.53 
C3c (mg/dl) 1.43  0.45 
C4c (mg/dl) 0.46  0.43 
CCHF, Crimean-Congo hemorrhagic fever; SD, standard deviation; AST, aspartate ami
creatine phosphokinase; PT, prothrombin time; INR, international normalized ratio; aPTT
protein; hs-CRP, high-sensitivity CRP; Ig, immunoglobulin; C3/C4, complement 3/4.
a D-dimer was evaluated in 43 patients; seven died.
b Protein C, protein S, and antithrombin III were evaluated in 27 patients; three died
c IgM, IgA, IgG, C3, and C4 were evaluated in 59 patients; nine died.
Table 3
Cut-off levels for prognostic factors
Level Sensitivity 
AST (U/l) 762 33.3 
ALT (U/l) 522 22.2 
CPK (U/l) 1952 33.3 
LDH (U/l) 1455 66.7 
Fibrinogen (mg/dl) 238 44.4 
PT (s) 17.9 33.3 
aPTT (s) 65.7 55.6 
Platelets ( 109/l) 17.500 100 
D-dimer (ng/ml) 6571 85.7 
CRP (mg/l) 48.5 44.4 
hs-CRP (mg/l) 46.2 33.3 
IgM (mg/dl) 1.7 61.7 
IgG (mg/dl) 15.7 48.9 
C3 (mg/dl) 1.4 46.8 
C4 (mg/dl) 0.4 29.8 
PPV, positive predictive value; NPV, negative predictive value; AUROC, area under the re
aminotransferase; CPK, creatine phosphokinase; LDH, lactate dehydrogenase; PT, prothro
CRP, high-sensitivity CRP; Ig, immunoglobulin; C3/C4, complement 3/4.the results, AST, LDH, PT, INR, aPTT, platelet count, ﬁbrinogen, CRP,
hs-CRP, IgG, IgM, C3, C4, and D-dimer levels differed signiﬁcantly
between the two groups. On the other hand, there was no
statistically signiﬁcant difference between the groups regarding
ALT, CPK, WBC, prealbumin, ceruloplasmin, protein C, protein S,
antithrombin III, and IgA.
ROC analysis was performed for the statistically signiﬁcant
parameters, and cut-off values with high sensitivity and speciﬁcity
are presented in Table 3.
4. Discussion
Four thousand four hundred and ﬁfty-three patients have been
diagnosed with CCHF in Turkey since 2002;11 53% of these patients
have been male and 47% female.12 The gender distribution was
similar in our patients: 54.3% were male and 45.7% were female.Fatal CCHF (n = 9) p-Value
1727  3513 p = 0.009
428  741 p = 0.107
2011  1626 p = 0.006
1307  1269 p = 0.061
18.37  6.61 p = 0.003
1.97  1.41 p = 0.005
81.98  24.98 p < 0.001
4.988  4.817 p = 0.289
11.444  4.693 p < 0.001
300.3  171.9 p = 0.027
59  61 p = 0.004
9356  1555 p = 0.002
0.10  0.03 p = 0.071
42.3  50.1 p = 0.049
0.23  0.1 p = 0.307
67.4  28.9 p = 0.355
57.0  4.3 p = 0.817
83.7  30.0 p = 0.176
1.25  0.47 p = 0.003
2.98  1.17 p = 0.235
13.13  4.72 p = 0.040
1.08  0.42 p = 0.048
0.22  0.14 p = 0.025
notransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CPK,
, activated partial thromboplastin time; WBC, white blood cell count; CRP, C-reactive
.
Speciﬁcity PPV NPV AUROC
96.7 60 90.6 0.773
98.3 66.6 89.5 0.663
96.7 60 90.6 0.694
90.0 50 94.8 0.785
95.1 57.1 92 0.270
90.0 33.3 90 0.810
95.0 70 96.6 0.944
75.4 37.5 100 0.105
72.2 37.5 96.2 0.952
95.1 57.1 92.0 0.793
88.9 27.2 89.8 0.676
83.3 35.7 93.5 0.202
83.3 29.4 92 0.307
83.3 28.5 91.6 0.314
75.0 23 85 0.289
ceiver operating characteristic curve; AST, aspartate aminotransferase; ALT, alanine
mbin time; aPTT, activated partial thromboplastin time; CRP, C-reactive protein; hs-
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population is farmers and stockbreeders.1 In a similar way, most of
our cases were farmers living in endemic areas, while four of the
patients had a history of visiting endemic areas.
According to Turkish Ministry of Health records, tick contact is
found to be present in 68.7% of Turkish CCHF patients.12 Of our
cases, 75.7% had a tick bite and/or tick contact history, and 24.3%
had no known tick contact. The mean duration between the onset
of symptoms and admission to hospital has been reported to be 5.5
days in Turkey,1 whereas this duration was found to be 3.6 days in
the current study. This difference may be explained by the
increased awareness of this disease in the population over time.
During the follow-up period, 27 (38.6%) patients had hemor-
rhages. According to previous reports, bleeding starts between the
third and sixth days of symptoms2 and continues for 2 or 3 days.1 In
our patients bleeding started at 3.9 days of symptoms and the
mean duration of bleeding was 3.1 days.
The fatality rate in CCHF patients varies between 3% and 30%.1
The rate is reported to be around 5% in Turkey,11 however in this
study the fatality rate was found to be 12.9%. This may be explained
by the fact that our hospital is a reference hospital, and for this
reason patients in a poorer condition were referred to our hospital.
Similarly, another reference hospital has reported their CCHF
fatality rate as 15%.9 Deaths generally occur after the ﬁfth day of
the disease.1 In our study, death occurred at a mean of 7 days. The
duration of hospitalization has been reported to be 10–14 days,1
and similarly, the mean time to discharge for our patients was 11.2
days.
Since the aim of this study was to re-evaluate existing fatality
parameters and to suggest new predictor factors for fatality that
would help to estimate the prognosis of the disease, the clinical
history and biochemical–hematological parameters of the patients
who survived and died were compared. When other criteria such
as age, gender, history of tick contact, date of admission to hospital,
and onset and duration of hemorrhage were compared, there was
no statistical difference between the two groups. Similarly, no
statistical difference was reported regarding fatality in otherTable 4
Comparison of our ﬁndings with those of other studies in terms of predictors of fatalit
Swanepoel et al. 19896 Bakır et al. 20057 Ergo¨n
Sex - No No 
Age - No No 
Tick exposure - No - 
Ecchymosis No No No 
Melena No - Yes 
Hematemesis No - Yes 
Somnolence No - Yes 
Elevated AST Yes Yes Yes 
Elevated ALT Yes No Yes 
Elevated CPK No Yes No 
Elevated LDH No Yes No 
Fibrinogen Yes - Yes 
PT elongation - - Yes 
aPTT elongation Yes - Yes 
Elevated INR - Yes - 
Thrombocytopenia Yes Yes Yes 
D-dimer - - - 
CRP - - - 
hs-CRP - - - 
Leukocytosis Yes No No 
IgA - - - 
IgM - - - 
IgG - - - 
C3 - - - 
C4 - - - 
CCHF, Crimean-Congo hemorrhagic fever; AST, aspartate aminotransferase; ALT, alanin
prothrombin time; aPTT, activated partial thromboplastin time; INR, internationa
immunoglobulin; C3/C4, complement 3/4.studies when comparing age, gender, and tick contact (Table 4).6–10
Only in the study performed by Fıs¸ gın et al. was age reported as a
factor determining the prognosis.10
Although the most common symptoms of CCHF patients are
high fever, fatigue, headache, and myalgia, the symptoms of
nausea, vomiting, and diarrhea are also found.5 In this study,
fatigue was the most common symptom (95.7%), followed by high
fever, myalgia, nausea, vomiting, and headache. Diarrhea was
observed less frequently than the other symptoms. When the
symptoms of patients who were discharged with recovery and the
patients who died were compared, similar to other studies, no
signiﬁcant difference was found between the groups.
The presence of hemorrhage is the most important factor
predictive of fatality.13 Bleeding has been reported to occur in all
patients who die.14 Similarly in our study, the presence of
hemorrhage was the most important factor predictive of fatality.
In CCHF patients, nasal, vaginal, skin, gastrointestinal, urinary
system, and respiratory system hemorrhages are the most
commonly reported.8 In this study epistaxis was the most common
bleeding, followed by vaginal, gingival, and skin bleeding,
hematemesis, and melena with diminishing frequencies. Bleeding
in more than one system was observed in patients who died. Thus,
it was difﬁcult to determine which type of bleeding was most
important in terms of fatality. We tried to determine the
importance of the systems for predicting fatality by grouping
the patients into minor and major bleeding groups. While none of
the patients died in the minor bleeding group, nine of the 10
patients in the major bleeding group died.
There are some typical biochemical and hematological changes
in CCHF patients. Thrombocytopenia, leukopenia, AST, ALT, LDH,
and CPK elevation, aPTT and PT prolongation, INR elevation, and a
decrease in ﬁbrinogen are observed in these patients.1,2 In addition
to these parameters we evaluated CRP, hs-CRP, prealbumin,
ceruloplasmin, D-dimer, protein C, protein S, antithrombin III,
IgA, IgM, IgG, C3, and C4 levels and compared them in the fatal
CCHF and non-fatal CCHF groups. There was a statistically
signiﬁcant difference between the groups regarding CRP, hs-CRP,y in CCHF
u¨l et al. 20068 C¸evik et al. 20089 Fıs¸ gın et al. 200910 Our study
No No No
No Yes No
- - No
Yes - No
Yes - Yes
Yes - Yes
Yes No -
Yes Yes Yes
Yes Yes No
Yes Yes No
Yes Yes Yes
No - Yes
Yes Yes Yes
Yes Yes Yes
- - Yes
Yes Yes Yes
- - Yes
- - Yes
- - Yes
No - No
- - No
- - Yes
- - Yes
- - Yes
- - Yes
e aminotransferase; CPK, creatine phosphokinase; LDH, lactate dehydrogenase; PT,
l normalized ratio; CRP, C-reactive protein; hs-CRP, high-sensitivity CRP; Ig,
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dimer levels were higher in the fatal CCHF group, IgM, IgG, C3, and
C4 levels were found to be decreased in these patients. It has been
reported that speciﬁc IgG and IgM are not developed in some fatal
CCHF cases.15 In this study, non-speciﬁc IgG and IgM average levels
were found to be lower in fatal CCHF cases and complement levels
were also lower due to consumption in this group. There were no
statistically signiﬁcant difference regarding protein C, protein S,
and antithrombin III levels.
A comparison of the studies of biochemical parameters that
could be factors predictive of fatality is presented in Table 4. In
these studies, elevation of AST, low platelet counts, prolongation of
aPTT and PT, and elevated INR values were found to be signiﬁcant.
In the current study and in the study performed by Bakır et al.,7
differences in ALT levels were not found to be signiﬁcant. Although
the mean ALT level in patients who survived was 137 U/l and in
patients who died was 437 U/l, because of the wide distribution of
the values, no statistical signiﬁcance was reached. Similarly, mean
CPK values were measured as 588 and 1307 in non-fatal CCHF and
fatal CCHF patients, respectively, but no signiﬁcant difference was
detected. Low ﬁbrinogen levels were found to be signiﬁcant in all
studies except the study performed by C¸evik et al.9 A high WBC
count was found to be signiﬁcant only in the study conducted by
Swanepoel et al.,6 but not in the other ﬁve studies in the
comparison. LDH levels were found to be signiﬁcant in all studies
except for those performed by Swanepoel et al.6 and Ergo¨nu¨l et al.8
While Swanepoel et al.6 reported that AST >200 U/l, ALT >150
U/l, WBC >10  109/l, platelets <20  109/l, and ﬁbrinogen
<110 mg/dl were signs of a worse prognosis, Ergo¨nu¨l et al.8
underlined the signiﬁcance of AST 700 U/l (sensitivity 16%,
speciﬁcity 100%) and ALT 900 U/l (sensitivity 43%, speciﬁcity
98%) levels. Moreover, C¸evik et al.9 reported that an aPTT >60 s and
platelet count <20  109/l are important prognostic factors. In this
study, cut-off values of prognostic factors were as follows: AST
>762 U/l; ALT >522 U/l; CPK >1952 U/l; LDH >1455 IU/l;
ﬁbrinogen <238.5 mg/dl; PT >17.9 s; aPTT >65.7 s; platelet count
<17.5  109/l; D-dimer >6571 mg/dl; CRP >48.5 mg/l; hs-CRP
>46.2 mg/l; IgM <1.7 mg/dl; IgG <15.7 mg/dl; C3 <1.4 mg/dl; C4
<0.4 mg/dl. In this study, factors other than AST and ALT levels and
platelet counts are suggested as prognostic factors for the ﬁrst
time, and these need to be further evaluated in future studies.
CCHF is an important infectious disease that may cause loss of
labor force and death, and is still an epidemic disease in our
country. Estimating the factors predictive of fatality is essential in
order to take the necessary possible precautions. Thus, it is
important to re-evaluate the existing parameters that have beenshown to be related with fatality and to suggest new predictor
factors for fatality.
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